ERBB2 and breast neoplasm: The unpublished data shows that MEDI4276 can inhibit D2F2/E2 tumor growth and reduce the number of HER2-positive cells and ALDHhigh CSCs by inducing significant host immune responses of CD3+ and CD19+ TILs in mouse breast tumor D2/F2 and TNBC 4T1, with enforced expression of HER2, D2F2/E2, and HER2-4T1.